CA CMA - Cardiol Therapeutics Corp CFO

CRDL Stock  CAD 3.19  0.12  3.63%   

Insider

CA CMA is Corp CFO of Cardiol Therapeutics Class
Address 2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5
Phone289 910 0850
Webhttps://www.cardiolrx.com

Cardiol Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.4535) % which means that it has lost $0.4535 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9211) %, meaning that it generated substantial loss on money invested by shareholders. Cardiol Therapeutics' management efficiency ratios could be used to measure how well Cardiol Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of May 2024, Return On Tangible Assets is likely to drop to -0.81. In addition to that, Return On Capital Employed is likely to drop to -1.1. At this time, Cardiol Therapeutics' Non Current Assets Total are very stable compared to the past year. As of the 29th of May 2024, Intangible Assets is likely to grow to about 404.7 K, while Total Assets are likely to drop about 38.4 M.
The company has accumulated 72.87 K in total debt with debt to equity ratio (D/E) of 1.0, which is about average as compared to similar companies. Cardiol Therapeutics has a current ratio of 24.18, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Cardiol Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Cardiol Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cardiol Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cardiol to invest in growth at high rates of return. When we think about Cardiol Therapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Glenn IvesWheaton Precious Metals
N/A
Renee McKenzieOpen Text Corp
49
R GillinWheaton Precious Metals
70
Howard CPAOpen Text Corp
60
PEng PEngWheaton Precious Metals
59
Craig StilwellOpen Text Corp
N/A
Mark McClendonCCL Industries
N/A
Genevive GosselinGildan Activewear
N/A
Luc JobinGildan Activewear
59
P JenkinsOpen Text Corp
59
Gunther BirknerCCL Industries
51
Michael AcedoOpen Text Corp
43
Jamie BeirnesWheaton Precious Metals
N/A
Jason PrattWaste Connections
39
John PerkeyWaste Connections
42
Cardiol Therapeutics Inc., a biotechnology company, engages in the research and commercial development of proprietary drug formulations for the treatment of heart failure and cancer. The company was incorporated in 2017 and is headquartered in Oakville, Canada. CARDIOL THERAPEUTICS operates under Biotechnology classification in Canada and is traded on Toronto Stock Exchange. It employs 6 people. Cardiol Therapeutics Class (CRDL) is traded on Toronto Exchange in Canada and employs 6 people. Cardiol Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Cardiol Therapeutics Leadership Team

Elected by the shareholders, the Cardiol Therapeutics' board of directors comprises two types of representatives: Cardiol Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cardiol. The board's role is to monitor Cardiol Therapeutics' management team and ensure that shareholders' interests are well served. Cardiol Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cardiol Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Andrew MD, Chief Development
Trevor Burns, Investor Relations
Bernard BSc, Chief Officer
MBA MBA, CEO Pres
David MBA, CEO President
CA CMA, Corp CFO

Cardiol Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cardiol Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Cardiol Therapeutics is a strong investment it is important to analyze Cardiol Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiol Therapeutics' future performance. For an informed investment choice regarding Cardiol Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Complementary Tools for Cardiol Stock analysis

When running Cardiol Therapeutics' price analysis, check to measure Cardiol Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardiol Therapeutics is operating at the current time. Most of Cardiol Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cardiol Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardiol Therapeutics' price. Additionally, you may evaluate how the addition of Cardiol Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.